ROSUVASTATIN 10mg. IP + CLOPIDOGREL 75mg. IP

A combination therapy of lipid-lowering and an antiplatelet agent is widely used in the management of cardiovascular diseases. (Chen Ning, 2021) Manages elevated lipid levels and reduces the risk of cardiovascular events in patients with hyperlipidemia. (Chen Ning, 2021) Effectively treats hypercholesterolemia with an excellent effect of lowering blood lipids. (Hongyun Gao, 2022) Improves the lipid profile, enables patients to achieve lipid goals and slows the progression of atherosclerosis and improves cardiovascular outcomes. (Schuster, 2007) Lowers both total cholesterol and low-density lipoprotein cholesterol levels and increases high-density lipoprotein cholesterol levels. (Han, 2019) Ameliorates cardiac function and reduces the levels of blood lipids and inflammatory factors in elderly patients with coronary heart disease. (Hongyun Gao, 2022) Alleviates and blocks the progression of atherosclerosis and stabilizes atherosclerotic plaques. (Hongyun Gao, 2022) Lowers the risk of cardiovascular disease and coronary events like heart attack, stroke, and heart-related chest pain. Decreases secondary vascular events such as thromboembolism in patients with atherosclerosis. (Han, 2019) Possesses excellent inhibitory properties of platelet aggregation and reduces cardiovascular risks in patients with multiple co-morbid conditions such as stroke, myocardial infarction and atherosclerosis. (Ramesh Mullangi, 2009)